Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
Related to this article
The regulatory path to approval for RP1 plus nivolumab in anti–PD-1–pretreated melanoma ran through 3 BLAs, 2 CRLs, and a divided advisory committee vote.
Advertisement
Advertisement
Trending on OncLive
1
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
2
Namodenoson Generates Longer-Than-Anticipated OS Advanced HCC
3
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
4
New Surgery Offers New Treatment Options for Patients with Advanced Abdominal Cancers
5